Table 1. Clinicopathological features of patients.
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | |
|---|---|---|---|---|---|---|---|---|---|
| Age at diagnosis, years | 66 | 68 | 26 | 36 | 55 | 52 | 58 | 45 | 41 |
| Gender | F | F | F | M | F | F | F | M | M |
| Steatosis grade | 1 | 2 | 1 | 1 | 2 | 2 | 3 | 1 | 3 |
| % Steatotic hepatocytes | 8 | 40 | 10 | 10 | 35 | 35 | 80 | 10 | 70 |
| Acinar zone | 3 | 2+3 | Non-zonal | 3 | 3 | 3 | Pan-zonal | Non-zonal | 2+3 |
| Hepatocyte ballooning | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Lobular inflammation | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Portal inflammation | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| Nuclear glycogenation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Megamitochondria | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Lipogranulomas | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 |
| SAF activity score | 1 | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 1 |
| NAS score | 2 | 4 | 1 | 2 | 3 | 3 | 5 | 2 | 4 |
| Fibrosis stage | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
F, female; M, male; NAS, non-alcoholic fatty liver disease (NAFLD) activity score; SAF, steatosis, activity and fibrosis.